Society demands that transparency is further developed in the way in which companies relate to their different stakeholders: not only is information regarding results demanded, but also and especially, the way in which these are obtained.
Transparency generates trust, is proof of independence and aids explain behaviors. All of the above are especially critical concepts when it is healthcare the field of work involved.
It is in this context that the disclosure initiative of the pharmaceutical industry is situated, consisting in making public the relationships it maintains with healthcare organisations and healthcare professionals, by disclosing the transfers of value derived from these interactions.
The initiative responds to a voluntary commitment of the pharmaceutical companies that have signed off the Code of Practice, approved in 2014, and it is also of a pioneer nature. In this way, one of the most regulated and self-regulated industries in the world can also turn into the reference point in transparency for many other sectors.
Along 2016, the pharmaceutical industry shall publish the transfers of value made to healthcare professionals and healthcare organisations derived from donations, educational and scientific meetings, fees for service and R&D. Everyone’s collaboration shall perfect to process to turn it into a key tool for the explanation of industry’s relationships with our main stakeholders.
This initiative is also developed in other countries of the European Union. The diversity of healthcare and pharmaceutical models make a comparison of said collaborations and the dimension of the transfers of value derived from them a complicated one.
The Spanish pharmaceutical industry defends the importance of the work it carries out for healthcare professionals and healthcare organisations to continue at the forefront of scientific knowledge worldwide. This is another reason to make it transparent.
More information availabe in the page disclosure documents.